MedTrace Logo

Impact of Pasireotide on Postoperative Pancreatic Fistulas Following Distal Resections

NCT04281680 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 258

Last updated 2020-02-24

No results posted yet for this study

Summary

Between 2000 and 2016 258 distal pancreatectomies were performed at our University Hospital which were included in our analysis. Pasireotide was used in between July 2014 and April 2016. Patients received 900-ug pasireotide administered twice daily perioperatively. We analyzed patients who received octreotide treatment separately. Complications such as fistulas (POPF), delayed gas-tric emptying (DGE), postoperative hemorrhage (PPH), reoperations and mortality were recorded and analyzed 90 days postoperatively

Conditions

  • Surgical Complications

Interventions

DRUG

Pasireotide 0.9 MG/ML

900-ug pasireotide administered subcutaneously twice daily for a week or until discharged from the hospital

Sponsors & Collaborators

  • Helsinki University Central Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-07-01
Primary Completion
2016-04-30
Completion
2016-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04281680 on ClinicalTrials.gov